SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.

Novo Nordisk - ADR

Novo Nordisk A/S

Novo Nordisk is capturing significant attention as investors weigh the competitive momentum of oral GLP-1 weight-loss medications against rival Eli Lilly. The community is actively debating the company's valuation, recent AI partnership, and the long-term impact of evolving prescription script data on its market position.

Zebec's integrated products - real time payroll apps, on-chain payments infrastructure and networked DePIN - serve companies of all sizes, merchants and individuals and help transcend the boundaries of traditional banking and diminish the role of financial intermediaries.

Zebec Network

Zebec Network (ZBCN) is generating intense community buzz as investors eye upcoming industry events and potential partnership announcements that could catalyze a shift in its market trajectory. While some participants urge caution regarding volatility and past performance, many are actively accumulating tokens, citing the project's real-world utility and long-term potential as key reasons for their bullish conviction.

Intellia Therapeutics, Inc. is a clinical stage genome editing company, which engages in the development of curative therapeutics using the CRISPR/Cas9 system. Its CRISPR/Cas9 system transforms medicine by both producing therapeutics that permanently edit and/or correct disease-associated genes in the human body with a single treatment course, and creates engineered cells that can treat oncological and immunological diseases. The company was founded by Andrew May, Luciano Marraffini, Rodolphe Barrangou, Nessan Bermingham, Rachel Haurwitz, Erik Sontheimer, Jennifer Doudna, and Derrick Rossi in May 2014 and is headquartered in Cambridge, MA.

Intellia Therapeutics Inc

Intellia Therapeutics is drawing significant attention as investors speculate on a potential short squeeze, fueled by a high short interest and anticipation surrounding upcoming Phase 3 clinical data. The community is actively debating the impact of pending regulatory decisions, with sentiment split between those expecting a major breakout on positive trial results and others wary of ongoing market volatility and dilution risks.

APE fuels culture. Backed by the best club in the world and hundreds of thousands of holders worldwide, it’s the token for digital and IRL communities, builders, creators, collectors, gamers, and beyond.  APE is the native gas token of ApeChain and is available across multiple ecosystems including Ethereum, Arbitrum, Solana and HyperLiquid.z  ApeCoin's mission is is to supercharge its ecosystem by supporting high-quality builders &amp; reinforcing 3 core pillars: ApeChain, Bored Ape Yacht Club, and Otherside.

ApeCoin

ApeCoin is seeing a surge in community interest and trading volume, driven by speculation over a potential price breakout and ongoing buzz regarding its ecosystem and NFT-linked utility. While some investors are bullish on recent technical patterns and market sentiment, others remain cautious, debating whether the movement is a genuine recovery or a temporary liquidity trap.

X-Energy, Inc. operates as an energy company The firm focuses on modular nuclear reactors and fuel technology for clean energy generation. The company was founded by Kam Ghaffarian and Eben Mulder on 2009 and is headquartered in Rockville, MD.

X-Energy Inc. - Ordinary Shares- Class A

X-energy Inc

X-energy is capturing intense community interest during its market debut, driven by its status as an Amazon-backed nuclear startup focusing on small modular reactor technology to meet surging AI data center energy demand. Investors are actively debating the company's long-term potential versus valuation concerns, with many closely watching for price stabilization as the stock navigates the high-volatility environment typical of major new public listings.

POET Technologies, Inc. engages in the designing, developing, manufacturing and sale of opto-electronic solutions for the sensing, data communications and telecommunications markets. It developed POET Optical Interposer platform, which allows the integration of electronic and photonic devices into a single multi-chip module. The company was founded on November 14, 1985 and is headquartered in Toronto, Canada.

POET Technologies Inc

POET Technologies is seeing massive volume and price appreciation driven by intense community interest, a potential short squeeze, and mounting speculation regarding its integration into AI-driven data center infrastructure. Investors are actively discussing the company's proprietary photonic technology and its expanding role within the supply chains of major hyperscalers, with community sentiment leaning heavily bullish as short-interest dynamics continue to fuel momentum.

Compass Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of proprietary antibody therapeutics. Its platform includes common light chain-focused antibody discovery, human display for antibody tuning, stitchmabs, and highly modular and manufacturable bispecific candidates. The company was founded by Thomas J. Schuetz in 2014 and is headquartered in Boston, MA.

Compass Therapeutics Inc

Compass Therapeutics is generating significant market interest ahead of the anticipated topline results for secondary endpoints from its Phase 2/3 COMPANION-002 study in biliary tract cancer. Community sentiment is largely focused on the binary event risk and the potential for a major stock re-rating should the trial prove successful.

Atomera, Inc. engages in the development, commercialization, and licensing of proprietary processes and technologies for the semiconductor industry. It developed Mears Silicon Technology, which increases performance and power efficiency in semiconductor transistors. The company was founded by Robert Mears on November 26, 2001 and is headquartered in Los Gatos, CA.

Atomera Inc

Atomera Inc. is seeing intense community discussion driven by speculation regarding potential commercial licensing deals with major semiconductor players for its Mears Silicon Technology, particularly following expanded collaborations and industry demand for next-generation transistor efficiency. While bulls point to technical validation and high-volume wafer runs as catalysts for a major re-rating, bears continue to cite the lack of sustained revenue and historical patterns of share price dilution.

Comcast Corp. engages in the provision of video, Internet, and phone services. It operates through the following segments: Residential Connectivity and Platforms, Business Services Connectivity, Media, Studios, and Theme Parks. The Residential Connectivity and Platforms segment consists of residential broadband and wireless services and Sky-branded entertainment television networks and advertising. The Business Service Connectivity segment offers broadband, wireline voice and wireless services through small to medium customers and large enterprises through the HFC network. The Media segment consists of NBCUniversal’s television and streaming platforms, including national, regional, and international cable networks. The Studios segment focuses on NBCUniversal’s film and television studio production and distribution operations. The Theme Parks segment operates Universal theme parks in Orlando, Florida, Hollywood, California, Osaka, Japan, and Beijing, China. The company was founded by Ralph Roberts in 1963 and is headquartered in Philadelphia, PA.

Comcast Corp - Ordinary Shares - Class A

Comcast Corp

Comcast is currently trending as investors weigh the company's decision to maintain financial discipline by exiting the bidding war for Warner Bros. Discovery against the upcoming spinoff of its cable networks into the new Versant Media Group entity. The community remains divided, with some investors praising the stock's low valuation and dividend yield, while others express frustration over persistent broadband subscriber losses and the stock's lack of upward momentum.

Berkshire Hathaway, Inc. is a holding company, which engages in the provision of property and casualty insurance and reinsurance, utilities and energy, freight rail transportation, finance, manufacturing, and retailing services. It operates through the following segments: Insurance, Burlington Northern Santa Fe, LLC (BNSF), Berkshire Hathaway Energy (BHE), Pilot Travel Centers (PTC), Manufacturing, McLane, and Service and Retailing. The Insurance segment includes the underwriting of GEICO, Berkshire Hathaway Primary Group, and Berkshire Hathaway Reinsurance Group. The BNSF segment involves the operation of railroad systems. The BHE segment focuses on regulated electric and gas utility, power generation and distribution, and real estate brokerage activities. The PTC segment consists of managing travel centers and marketing of wholesale fuel. The Manufacturing segment refers to industrial, consumer and building products, home building, and related financial services. The McLane segment covers the wholesale distribution of groceries and non-food items. The Service and Retailing segment relates to the provision of shared aircraft ownership programs, aviation pilot training, electronic components distribution, retailing businesses, automobile dealerships and trailer, and furniture leasing services. The company was founded by Oliver Chace in 1839 and is headquartered in Omaha, NE.

Berkshire Hathaway Inc. - Ordinary Shares - Class B

Berkshire Hathaway is trending as investors express significant frustration over the stock's recent underperformance relative to the broader market and a perceived lack of capital deployment by leadership. While some community members view current price levels as a potential value opportunity supported by buybacks, others are vocal in their criticism of the company's massive cash pile and the transition following Warren Buffett's tenure.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

The PEA put out by $IAUX used conservative numbers at 3K gold, 35 silver = NPV 4.9 (post royalty/converts 4B)  
 
I did a model at 3500 Au/40 Ag and value is there w/ Mineral Point (this is why $FNV has a covenant that funds be use to advance it) 
 
The primary risk to the equity is not the gold price, its prolong delay (6 months or more) on commissioning the autoclave, plus mineral point is not permittable for some reason which affects the royalty and converts.  
 
Since there&#39;s nothing new about this particular autoclave the risk of delay is low and since Mineral Point is standard open pit mine in NV the risk is also not receiving the permit to mine it. 
 
Gold will have to break below 2k/oz before any upside to equity evaporates.

Brandon

@AllinCapital problem with this stock is the constant dilution. yes the projects look appealing on the surface, but the dilution and the lack of cash flow are the negative aspects. If gold goes out of favor, like now, it could potentially cripple this.

StockTwits Web

halba

i-80 Gold Corp

Franco-Nevada Corporation

 used conservative numbers at 3K gold, 35 silver = NPV 4.9 (post royalty/converts 4B)  
 
I did a model at 3500 Au/40 Ag and value is there w/ Mineral Point (this is why 

 has a covenant that funds be use to advance it) 
 
The primary risk to the equity is not the gold price, its prolong delay (6 months or more) on commissioning the autoclave, plus mineral point is not permittable for some reason which affects the royalty and converts.  
 
Since there's nothing new about this particular autoclave the risk of delay is low and since Mineral Point is standard open pit mine in NV the risk is also not receiving the permit to mine it. 
 
Gold will have to break below 2k/oz before any upside to equity evaporates.